0000000000552241

AUTHOR

Diana Taylor

showing 2 related works from this author

A Forum on Theatre and Tragedy: A Response to September 11, 2001

2002

A Forum on Theatre and Tragedy in the Wake of September 11, 2001 Author(s): Diana Taylor, Una Chaudhuri, W. B. Worthen, Jennifer DeVere Brody, Harry J. Elam, Jr., Amy Villarejo, Jill Dolan, Sue-Ellen Case, Jill Lane, Antonio Prieto, Freddie Rokem, Ann Pellegrini, Christopher B. Balme, Alicia Arrizon, Sharon P. Holland, Brian Singleton, Michal Kobialka, Jose Esteban Munoz, Karen Shimakawa, Bob Vorlicky, Josh Kun, Roberta Uno, Alice Raynor, Richard Schechner, Marvin Carlson, Janelle Reinelt and Eli ... Source: Theatre Journal, Vol. 54, No. 1, Tragedy (Mar., 2002), pp. 95-138 Published by: The Johns Hopkins University Press Stable URL: http://www.jstor.org/stable/25069023 . Accessed: 25/04/201…

ScholarshipLiterature and Literary TheoryVisual Arts and Performing Artsmedia_common.quotation_subjectTragedyArt historyPerformance artSubject (documents)Artmedia_commonVisual artsTheatre Journal
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct